BMS’ Opdivo shown to improve five-year lung cancer survival
Bristol-Myers Squibb has unveiled “unprecedented” long-term survival data for its cancer immunotherapy Opdivo, showing that nearly one in six patients with previously-treated, advanced non-small cell lung cancer (NSCLC) were still alive at five years.
Read More
